Chemotherapy of Non-Small Cell Lung Cancer: Most Frequent Complications of Treatment and Methods of Dealing with them
https://doi.org/10.33667/2078-5631-2019-2-17(392)-43-48
Abstract
Chemoradiotherapy is the cornerstone in the treatment of patients with locally advanced lung cancer. However, according to official statistics in Russia, such treatment is extremely rare, despite the fact that the primary locally advanced lung cancer is detected in more than 30 % of cases. One of the most frequent obstacles for the wider use of chemoradiotherapy is its high toxicity for patients with intrathoracic tumors. This review presents the most common complications and methods for their prevention, treatment and control.
About the Authors
N. V. Dengina
Regional Clinical Cancer Centre, Ulyanovsk
Russian Federation
Russian Federation
T. V. Mitin
Oregon Health & Science University, Portland
United States
United States
Department of Radiation Medicine
M. V. Chernykh
Oncoradiological Centre of Podolsk City Clinical Hospital, Podolsk
Russian Federation
Russian Federation
References
1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
2. Chargari C, Soria JC, Deutsch E. Controversies and challenges regarding the impact of radiation therapy on survival. Annals of Oncology 00: 1–9, 2012
3. O’Rourke N, Roqué i Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010;6: CD 002140.
4. Auperin A, Le Pechoux С, Rolland E, et al. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer. J Clin Oncol 2010;28(13):2181–2190.
5. Vokes EE, Herndon II JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non– small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698–1704.
6. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883–5891.
7. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U. S. Oncology. J Clin Oncol 2008;26:5755–60.
8. Jalal SI, Riggs HD, Melnyk A, et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 2012;23:1730–1738
9. Состояние онкологической помощи населению России в 2017 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена, 2018.
10. Miller K et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016 Jul;66(4):271–89
11. Лактионов К. К., Артамонова Е. В., Бредер В. В., Горбунова В. А., Моисеенко Ф. В., Реутова Е. В., Сакаева Д. Д., Смолин А. В., Тер-Ованесов М. Д. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли 2018;8(3), спецвыпуск 2.
12. Ezer N, Smith CB, Galsky MD, et al. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III nonsmall cell lung cancer. Radiother Oncol. 2014 Aug;112(2):272–8.
13. Santana-Davila R, Devisetty K, Szabo A, et al: Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non–small-cell lung cancer: An analysis of Veterans Health Administration data. J Clin Oncol doi: 10.1200/JCO.2014.56.2587
14. Steuer CE, Behera M. et al. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA Oncol. 2017 Aug 1;3(8):1120–1129.
15. Vokes EE, Herndon JE, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191–4198
16. Werner-Wasik M: Treatment-related esophagitis. Semin Oncol 2005;32: S 60-S 66.
17. Palma DA et al. Predicting Radiation Pneumonitis after Chemoradiotherapy for Lung Cancer: An International Individual Patient Data Meta-analysis. Int J Radiat Oncol Biol Phys. 2013 February 1; 85(2): 444–450.
18. Parashar B, Edwards A, et al. Chemotherapy significantly increases the risk of radiation pneumonitis in radiation therapy of advanced lung cancer. Am J Clin Oncol. 2011 Apr;34(2):160–4.
19. Palma et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85(2):444–50.
20. Antonia SJ et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med 2017; 377:1919–1929.
21. Yılmaz UM, Erol S, et al. Chemoradiotherapy-Associated Myelosuppression: A Retrospective Analysis of Risk Factors for Patients with NonSmall Cell Lung Cancer. Eurasian J Pulmonol 2015; 17: 49–53
22. Сакаева Д. Д., Орлова Р. В., Шабаева М. М. Практические рекомендации по лечению инфекционных осложнений фебрильной нейтропении и назначению колониестимулирующих факторов у онкологических больных. Практические рекомендации RUSSCO, версия 2018.
23. Kishida Y, HIROSE T, et al. Myelosuppression induced by concurrent chemoradiotherapy as a prognostic factor for patients with locally advanced non-small cell lung cancer. Oncology Letters 2011;2: 949–955.
24. Cheng Y. et al. Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions. Oncotarget, 2017, Vol. 8, (No. 19), pp: 32228–32236.
25. Практические рекомендации по поддерживающей и сопроводительной терапии RUSSCO, версия 2018 г.
26. Yazbeck VY, Villaruz L, Haley M, Socinski MA. Management of Normal Tissue Toxicity Associated With Chemoradiation (Primary Skin, Esophagus, and Lung). Cancer J. 2013; 19(3): 231–237.
27. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25(25):3991–4008.
28. RTOG/EORTC Late Radiation Morbidity Scoring Schema URL: https://www.rtog.org/researchassociates/adverseeventreporting/rtogeortclateradiationmorbidityscoringschema.aspx
29. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010) U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute URL: http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf
Review
For citations:
Dengina N.V., Mitin T.V., Chernykh M.V. Chemotherapy of Non-Small Cell Lung Cancer: Most Frequent Complications of Treatment and Methods of Dealing with them. Medical alphabet. 2019;2(17):43-48. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-17(392)-43-48
Views:
634
Email this article 